Investment analysts at The Goldman Sachs Group initiated coverage on shares of Kestra Medical Technologies (NASDAQ:KMTS – Get Free Report) in a report issued on Monday,Benzinga reports. The brokerage set a “neutral” rating and a $24.00 price target on the stock. The Goldman Sachs Group’s price objective indicates a potential upside of 2.43% from the company’s previous close.
Separately, Stifel Nicolaus started coverage on Kestra Medical Technologies in a report on Monday. They set a “buy” rating and a $28.00 price target on the stock.
Get Our Latest Analysis on KMTS
Kestra Medical Technologies Price Performance
About Kestra Medical Technologies
We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution.
Recommended Stories
- Five stocks we like better than Kestra Medical Technologies
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- Lululemon Pulls Back Into Classic Dip-Buying Opportunity
- How to Evaluate a Stock Before BuyingÂ
- Cintas Delivers Earnings Beat, Signals More Growth Ahead
- High Dividend REITs: Are They an Ideal Way to Diversify?
- Analysts Say These 4 Low P/E Consumer Cyclical Stocks Are Buys
Receive News & Ratings for Kestra Medical Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kestra Medical Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
